Back to EZorb Newsletter Index

 

EZorb

 

EZORB MONTHLY NEWSLETTER JUL 28, 2007

In this issue:

1. Share Success: Letters From Readers
2.

Research News: Two Diabetes Drugs Double Heart Failure Risk

3. Useful Links
4. Calcium Absorption Test
5. What Are Others Saying About EZorb?
 

 

1. Share Success: Letters From Readers 

***************************************************

Letter I: From Ruth

Received at Testimonial Submit Form on Wednesday, June 27, 2007 at 09:10:29

 

Hi, my name is Ruth. I was told I had Fibromyalgia Oct. '05. Did extensive research and found EZorb. I started taking it Oct. 17th, '05. Started with a personal trainer Oct. 28th. My knees and hands were so swollen I had my rings changed from a size 6 to a size 9. I could hardly walk, had to rest often, was walking at least one mile, or more a day, had to stop that. Had to stop working in my yard, cleaning the house now took three or four days instead of one. Just being awake was painful. Sleeping was impossible. I thought my life was over.

 

I kept in touch with a very helpful gentleman P.Z. at the Elixir Industry about EZorb and what effect it was having on me. He would tell me to continue to take it twice a day and I would see results. At times I had no hope of ever getting better but did continue taking it.

 

My personal trainer said she could help me with fibromyalgia but she thought I had rheumatiod artritis also. Went to a specialist and indeed I do have both. She said I needed more help than she could give me. I tried other medications for a while but was getting nowhere.

 

Started wtih another personal trainer and stayed with the EZorb. The personal trainer told me of a health food product. In a matter of weeks the swelling had gone away and some of the pain. I continued to talk to the gentleman about EZorb and he said I would start feeling lots better.

 

I am so happy I listened to him and stayed with my program. EZorb is something that helped give me my life back and I will continue to take it the rest of my life.

 

I am not walking as much as I would like but I am able to work with the personal trainer two times a week now and feel better for it. Sleep much better and am enjoying life a lot more.

 

The best report I can give about EZorb is: Seven years ago I had a bone density test. I was told then I head osteroporosis and needed to take medication. I tried that and the side effects were not good. Took what I thought was an excellent calcium not knowing about EZorb at that time. I just had another bone density test and my report is too good to believe. My bone density has stayed the same as it was seven years ago. The doctor could hardly believe it due to the fact that I am seven years older and that makes me the young age of 76 years. Needless to say EZorb and exercise are a part of my life from now on. I am so grateful P.Z., with EZorb, was so patient with me and that I listened to him. I could have given up and he could have also.

 

I have recommended this product to so many people and will continue to do so. Thank you so much.

 

Ruth

 

Letter II: From E. Anonymous

Received at Testimonial Submit Form on Tuesday, May 15, 2007 at 14:15:56

(Unedited)

 

I cannot thank you enough for your EZorb capsules. I've been using them for almost 3 weeks and though my heel isn't completely better, I am able to walk without sharp pain. I was desperate to find something that helped. Your product also arrived within 3 days of when I ordered it. I expected to have to wait weeks. Thanks!!!

  

Letter III: From Donna, Bloomington, IL

Received at Testimonial Submit Form on Tuesday, March 06, 2007 at 11:33:19

(Unedited)

 

Hi, my name is Donna. I'm 53 years old and have been diagnosed with ostio. I too was offered fasomax. I refused and found EZorb over the internet. I'm postmenopausal and also refused to take hormone thearpy. My obgyn didn't even take a bone denisty test on me but offered treatment to prevent me from getting ostio.

 

I'm glad I refused. Since taking EZorb I have notice my nails getting really long and not brittle. I have never had long nails in my life and they were always brittle. I'm looking forward to getting another bone density test. I have much more energy and also am sleeping better at night. I'm also not having nearly as many hot flashes. Thank-you ezorb.

 

Donna

Bloomington, Il

Letter IV: From Lorraine, Detroit, MI

Received at Testimonial Submit Form on Tuesday, January 30, 2007 at 13:43:50

(Unedited)

 

Hi, my name is Lorraine. My bone density test resulted in 2.1 from 2.5 after I started taking EZorb. My doctor said I'm so pleased with you. He is still writing me prescriptions for Fosomex which I haven't taken since I discovered EZorb.

 

Detroit, Michigan

 

 

***************************************************

From the Desk of EZorb Newsletter Editor:

This newsletter is now read by over 50,000 subscribers worldwide. Success stories you contribute will have great impact on many people's life. Kindly email your story to sharesuccess @ ezorbonline.com. As always your private information will never be revealed to the public.

 

2. Research News: Two Diabetes Drugs Double Heart Failure Risk

 

Patients taking either of the diabetes drugs Avandia or Actos face twice the risk of developing heart failure compared to people not on the popular medications, a new study finds.

 

This means for every 50 patients with type 2 diabetes taking these drugs, one patient will develop heart failure within 26 months, according to the report released Friday and published in the August issue of Diabetes Care.

 

"Both Avandia and Actos double the risk of heart failure," concluded the lead author of the first study, Dr. Sonal Singh, an assistant professor of internal medicine at Wake Forest University School of Medicine. "We know these drugs increase the risk, but we found the risk is more substantial than suspected. This occurs at even the lowest dose and among young patients."

 

The report follows a U.S. government review released Thursday that found Avandia's heart risks are far higher than Actos'. That report sets the stage for an advisory panel hearing Monday that will examine whether Avandia's cardiovascular risks warrant a stronger warning label.

 

Avandia (rosiglitazone) and Actos (pioglitazone) are from the same family of diabetes drugs and used by more than 3 million diabetic patients across the United States.

 

The current product label warns against using these drugs in patients with more severe cases of heart failure. The label also warns that there is an increased risk of heart failure if the drugs are used in combination with insulin.

 

Singh's group, however, found that the risk wasn't limited to patients on insulin, and it was present even among patients without any risk factors for heart failure.

 

The government study, by a medical and safety review team at the Food and Drug Administration, found that patients are at much higher risk of heart problems if they take Avandia, compared to patients taking Actos. Avandia is especially hazardous to patients who are already on insulin, the report found, whereas Actos users can take insulin as well without fearing cardiac side effects, the New York Times reported.

 

That data could help decide whether or not Avandia remains on drug store shelves, experts said.

 

"A critical question to be resolved in determining appropriate regulatory action is whether the anticipated therapeutic benefit of rosiglitazone outweighs the demonstrated cardiovascular risk," one FDA reviewer concluded according to the Times report.

 

In the Diabetes Care study, Singh's team collected data on more than 78,000 patients taking either of the drugs. These patients were included in previously published studies and in case reports. Not only did the drugs double the risk of heart failure, but the increased risk was seen with both high and low doses, the team found.

 

Heart failure developed in some patients taking lower doses than are commonly prescribed. The average time for heart failure to develop was 24 weeks after starting the drugs, the researchers found.

 

Heart failure wasn't confined to older patients. Twenty-five percent of the patients who developed heart failure were under 60. In addition, both men and women developed heart failure while taking the drugs, Singh noted.

 

Singh's group suspect that Avandia and Actos may boost heart failure risk by encouraging fluid retention.

 

Current guidelines allow the use of these drugs in patients with early-stage heart failure. "Based on our information, that may have to change," Singh said.

 

Singh noted that there are alternative drugs available. "Doctors should be aware of the risk," he said. "Patients who are on these drugs and start developing symptoms of heart failure should see their doctor immediately, and patients not on these drugs should look at alternatives."

 

One expert believes that patients taking Avandia and Actos face not only an increased risk of heart failure, but also a 43 percent increased risk of heart attack.

 

"This hazard of heart failure is pretty well known for these drugs," said Dr. Steven E. Nissen, chairman of the department of cardiovascular medicine at the Cleveland Clinic. He noted that, in May, the FDA said it was going to mandate a "black box" warning about heart failure risk on the labels of these drugs.

 

That same month, Nissen published a paper in the New England Journal of Medicine that found that Avandia increased the risk of heart attack.

 

Since then, the controversy has continued, with both sides weighing in.

 

On Thursday, Mary Anne Rhyne, a spokeswoman for GlaxoSmithKline, which makes Avandia, responded to the new government review by saying the company continued to believe Avandia was safe, the Times reported.

 

"Across the extensive data we have, the science shows no increase in cardiovascular death, and does not support a difference in heart attack rates between Avandia and the other most commonly prescribed oral antidiabetics," Rhyne told the Times.

 

On Friday, the company's director of clinical development, Dr. Andy Zambanini, told HealthDay that Glaxo was "still in negotiation with the FDA about a new warning label on heart failure, and we expect to release that information soon."

 

Nissen believes that patients who are considering taking Avandia should discuss the decision with their doctor. "It is important that the totality of information be out there," he said. "But no patient should stop taking a medication [only] because they read a news report."

 

Another expert contends that the two drugs are safe if prescribed correctly.

 

"The risk for heart failure with these drugs may be one in 50, but if you can correctly identify who that person [at risk] is, you can safely treat the other 49 and not hurt anybody," said Dr. Larry Deeb, president for medicine and science at the American Diabetes Association.

 

Deeb believes the same holds true for the risk of heart attack.

The boost in risk of heart failure and heart attack does not warrant taking these drugs off the market, he added.

 

"They fit into the armamentarium of diabetes drugs if used properly," Deeb said.

 

Original Study Published in August issue of Diabetes Care

 

3. Useful Links

EZorb Online

Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now

 

4. Calcium Absorption Test

EZorb Calcium has set a new world record of absorption rate. You can compare EZorb with other calcium supplements by using the simple step-by-step instructions we provide. E-mail your request to test @ ezorbonline.com for a copy of the instructions.

 

5. What Are Others Saying About EZorb?

EZorb Calcium has restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb.

  

Back to EZorb Newsletter Index

 
 
  Copyright 2007 Elixir Industry